In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Myovant grants Pfizer sublicense option on relugolix and RVT602

Executive Summary

Under a deal concurrent with the closing of its $202mm initial public offering, Myovant Sciences Ltd. granted an affiliate of Pfizer Inc. the right of first negotiation (ROFN) to a sublicense to two male and female health drug candidates Myovant previously in-licensed from Takeda Pharmaceutical.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies